BridgeBio Pharma, Inc. (BBIO) has a MoatMap StockRank of 64/100 based on Quality (32/100), Value (47/100), and Momentum (67/100) factor scores. The current signal is HOLD. BridgeBio Pharma is a biotech company, typically high-risk and reliant on clinical success, rather than clear macro tailwinds. It does not fit the quality compounder criteria, often lacking profitability and a clear moat in its early stages.